New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery.

Détails

Ressource 1Télécharger: 32523529_BIB_D9403A530863.pdf (1236.31 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_D9403A530863
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery.
Périodique
Frontiers in pharmacology
Auteur⸱e⸱s
Spadaro A., Rao M., Lorenti M., Romano M.R., Augello A., Eandi C.M., Platania CBM, Drago F., Bucolo C.
ISSN
1663-9812 (Print)
ISSN-L
1663-9812
Statut éditorial
Publié
Date de publication
2020
Peer-reviewed
Oui
Volume
11
Pages
708
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Our study was aimed at assessing the retinal binding of a new synthetic Brilliant Blue G (BBG) derivative (pure benzyl-Brilliant Blue G; PBB) ophthalmic formulation, to improve vitreoretinal surgery procedure. Protein affinity of the new molecule was evaluated in vitro (cell-free assay) and in silico. Furthermore, an ex vivo model of vitreoretinal surgery was developed by using porcine eyes to assess the pharmacological profile of PBB, compared to commercial formulations based on BBG and methyl-BBG (Me-BBG). PBB showed a higher affinity for proteins (p < 0.05), compared to BBG and Me-BBG. In vitro and in silico studies demonstrated that the high selectivity of PBB could be related to high lipophilicity and binding affinity to fibronectin, the main component of the retinal internal limiting membrane (ILM). The PBB staining capabilities were evaluated in porcine eyes in comparison with BBG and Me-BBG. Forty microliters of each formulation were slowly placed over the retinal surface and removed after 30 s. After that, ILM peeling was carried out, and the retina collected. BBG, Me-BBG, and PBB quantification in ILM and retina tissues was carried out by HPLC analysis. PBB levels in the ILM were significantly (p < 0.05) higher compared to BBG and Me-BBG formulations. On the contrary, PBB showed a much lower (p < 0.05) distribution in retina (52 ng/mg tissue) compared to BBG and Me-BBG, in particular PBB levels were significantly (p < 0.05) lower. Therefore, the new synthetic Brilliant Blue derivative (PBB) showed a great ILM selectivity in comparison to underneath retinal layers. In conclusion, these findings had high translational impact with a tangible improving in ex vivo model of retinal surgery, suggesting a future use during surgical practice.
Mots-clé
Brilliant Blue G, drug design, inner limiting membrane, pucker, retina, vitreoretinal surgery
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/06/2020 15:53
Dernière modification de la notice
30/04/2021 6:15
Données d'usage